OptiBiotix Health (OPTI) Share Price, News & Analysis

Company Overview

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks. OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

Key Stats

• Today's Range: 17.16 to 18
• 50-Day Range: 15 to 22.60
• 52-Week Range: 10 to 35
• Volume: 339,691 shs
• Average Volume: 215,137 shs
• Market Capitalization: £17.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OPTI Stock Analysis - Frequently Asked Questions

How have OPTI shares performed this year?

OptiBiotix Health's stock was trading at GBX 18.05 at the beginning of 2025. Since then, OPTI stock has decreased by 3.6% and is now trading at GBX 17.40.
View the best growth stocks for 2025 here.

How were OptiBiotix Health's earnings last quarter?

OptiBiotix Health Plc (LON:OPTI) issued its quarterly earnings results on Thursday, September, 24th. The company reported ($0.70) earnings per share (EPS) for the quarter. OptiBiotix Health had a negative net margin of 524.43% and a negative trailing twelve-month return on equity of 36.76%.

How do I buy shares of OptiBiotix Health?

Shares of OPTI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of OptiBiotix Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OptiBiotix Health investors own include SkinBioTherapeutics (SBTX), IQE (IQE), Oracle (ORCL), Digital Globe Services (DGS), Derwent London (DLN), Petrofac (PFC) and IP Group (IPO).

Company Calendar

• Last Earnings: 9/24/2020
• Today: 2/22/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: LON:OPTI
• Previous Symbol: LON:CMI
• CUSIP: N/A
• CIK: N/A
• Web: www.optibiotix.com
• Phone: +44-20-79338780
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (3.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-3,094,178.44
• Net Margins: -524.43%
• Pretax Margin: N/A
• Return on Equity: -36.76%
• Return on Assets: -13.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.18
• Quick Ratio: 7.89

Sales & Book Value

• Annual Sales: £590,009.23
• Price / Sales: 28.88
• Cash Flow: GBX 2.01 per share
• Price / Cash Flow: 8.68
• Book Value: GBX 7.80 per share
• Price / Book: 2.23

Miscellaneous

• Outstanding Shares: 97,943,197
• Free Float: N/A
• Market Cap: £17.04 million
• Optionable: Not Optionable
• Beta: 1.71